WEED logo

Canopy Growth Corporation Stock Price

TSX:WEED Community·CA$553.0m Market Cap
  • 3 Narratives written by author
  • 1 Comments on narratives written by author
  • 58 Fair Values set on narratives written by author

WEED Share Price Performance

CA$1.32
-0.37 (-21.89%)
CA$4.82
Fair Value
CA$1.32
-0.37 (-21.89%)
72.6% undervalued intrinsic discount
CA$4.82
Fair Value
Price CA$1.32
AnalystHighTarget CA$4.82
AnalystConsensusTarget CA$2.33
AnalystLowTarget

WEED Community Narratives

·
Fair Value CA$4.82 72.6% undervalued intrinsic discount

Global Cannabis Legalization Will Unlock Medical And Wellness Markets

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
·
Fair Value CA$2.33 43.4% undervalued intrinsic discount

European Expansion And Operational Improvements Will Unlock Cannabis Potential

0users have liked this narrative
1users have commented on this narrative
42users have followed this narrative
·
Fair Value CA$0 n/aintrinsic discount

Poland Restrictions And Rising Costs Will Constrain Global Expansion

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
CA$4.82
72.6% undervalued intrinsic discount
Profit Margin
7.83%
Future PE
80.28x
Price in 2029
CA$5.79

Trending Discussion

Updated Narratives

WEED logo

WEED: German Medical Relaunch Will Drive Future Upside For The Stock

Fair Value: CA$2.33 43.4% undervalued intrinsic discount
42 users have set this as their fair value
1 users have commented on this narrative
0 users have liked this narrative
WEED logo

WEED: German Medical Relaunch And New Brand Portfolio Will Drive Upside

Fair Value: CA$4.82 72.6% undervalued intrinsic discount
4 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
WEED logo

Poland Restrictions And Rising Costs Will Constrain Global Expansion

Fair Value: CA$0 0% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet and slightly overvalued.

2 Risks
3 Rewards

Canopy Growth Corporation Key Details

CA$284.6m

Revenue

CA$205.1m

Cost of Revenue

CA$79.5m

Gross Profit

CA$342.5m

Other Expenses

-CA$262.9m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.62
27.95%
-92.38%
33.5%
View Full Analysis

About WEED

Founded
n/a
Employees
1128
CEO
Luc Mongeau
WebsiteView website
www.canopygrowth.com

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel. It also provides vaporizers and accessories; dried flower and pre-rolled joints, oil, and vapes and beverages; extracts and concentrates, such as softgel capsules; and cannabis edibles, including gummies. In addition, the company operates e-commerce shop; medical cannabis online distribution platform; and an online medical cannabis clinic. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Abba Medix, Storz & Bickel, Wana, and Claybourne, Apollo, Canada House, R’belle, LowKey, MTL Cannabis, DeeLish, DOJA brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Recent WEED News & Updates

Narrative Update Jun 18

WEED: German Medical Relaunch Will Drive Future Upside For The Stock

Analysts have trimmed their fair value estimate for Canopy Growth to CA$2.33 from CA$2.38, citing updated assumptions around revenue growth, profit margins and the future P/E they apply to the stock. What's in the News for Canopy Growth Canopy Growth relaunched its Tweed brand in the German medical market, introducing three cannabis strains developed by its wholly owned subsidiary MTL Cannabis Corp., with plans for up to five MTL-derived strains in June 2026 and further portfolio expansion through the year.

Recent updates

No updates